In Vitro Properties and Virulence of Contemporary Recombinant Influenza B Viruses Harboring Mutations of Cross-Resistance to Neuraminidase Inhibitors

Three neuraminidase inhibitors (NAIs: Oseltamivir, zanamivir and peramivir) are currently approved in many countries for the treatment of influenza A and B infections. The emergence of influenza B viruses (IBVs) containing mutations of cross-resistance to these NAIs constitutes a serious clinical th...

Descripció completa

Dades bibliogràfiques

Autors principals:	Clément Fage, Yacine Abed, Liva Checkmahomed, Marie-Christine Venable, Guy Boivin
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2018-12-01
Col·lecció:	Viruses
Matèries:	influenza B resistance fitness mouse model and neuraminidase mutation
Accés en línia:	http://www.mdpi.com/1999-4915/11/1/6
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!